secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001628280-26-025508
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics raises ~$463.5M in underwritten public offering of 7.475M shares at $62.00/share
--------------------------------------------------------------------------------

- Gross proceeds of ~$463.5M from 7.475M shares including full exercise of over-allotment option at $62.00/share.
- Proceeds to fund IBD and rheumatic disease programs, including preclinical, clinical trials, manufacturing, and Phase 3 readiness.
- Underwriting agreement with Jefferies, Goldman Sachs, Evercore, and Guggenheim Securities as representatives.
- Offering closed on April 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000162828026025508/0001628280-26-025508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000162828026025508/syre-20260414.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-025508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer